Navigating the IRA: What Biopharmas Need to Know
Presented by BioCentury & Putnam
ON-DEMAND RECORDING
RECORDED: Thursday, March 30, 2023
The drug price-setting provisions of the Inflation Reduction Act (IRA) will reconfigure the commercial landscape in the U.S., forcing biopharma companies and their investors to develop new strategies for R&D and business success.
BioCentury, Putnam and a panel of industry experts discuss the Inflation Reduction Act and explain how the IRA will:
- Impact your pipeline prioritization and portfolio investment strategies.
- Affect when and whether you seek approvals for multiple indications.
- Alter your business development and deal-making strategies.
- Influence your orphan drug development strategies.
- Change the calculation for venture investments in biotech.
Hosted By
